Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has approved and appointed Tanvir Khandaker, M.D., to its Board of Directors.
Dr. Tanvir Khandaker, a former researcher at the Harvard Medical School and affiliated Brigham & Women's and Massachusetts General Hospitals, has experience in the healthcare and biotechnology fields. Dr. Khandaker conducted bench research targeting autoimmune disorders and inherent malignancies. He was an adjunct instructor at the Fisher College in Boston. Prior to that, he conducted clinical research at Mount Sinai Hospital in New York.
Dr. Khandaker has a singular focus in healthcare and life sciences, including extensive industry knowledge in those areas. He has been a stern advocate of biotech and innovative technology-driven healthcare. From 2002 to 2004, Dr. Khandaker operated his own independent investment firm, Khandaker Partners, which reviewed and conducted fundamental analysis of biotech and healthcare publicly traded companies.
Dr. Khandaker received his Medical Degree from Mitford Medical College, Dhaka, Bangladesh, which is affiliated with the Royal College of London. A national board scholar of Dhaka University, Dr. Khandaker graduated from Mitford Medical College with distinction in 1995. He was a practicing physician in general medicine before he joined the Biotech industry on an academic research capacity. Dr. Khandaker is an active member of AAPI (American Association of Physicians of Indian Origin) and TiE (The Indus Entrepreneurs) Tri-State region.
"I am looking forward to working with Nutra Pharma's team as I believe in its licensing model in the Biopharmaceutical and Nutraceutical industries," commented Dr. Tanvir Khandaker. "The Company's unique acquisition and licensing model targets high value therapeutics to build a robust, diversified portfolio. For example, the company is working on a therapeutic for Multiple Sclerosis, a disease that is currently underserved by the available treatment options. The market for MS therapeutics is expected to grow to almost $7 billion by 2009, according to a report by Navigant Consulting," he added.
"Dr. Khandaker's background in medical research as well as his experience in the public markets will be invaluable resources to Nutra Pharma," stated Rik Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "I'm very excited to be working with Dr. Khandaker. He adds necessary experience to the Board to move our business plan forward," he concluded.<.font>
Commenting on how he envisions his contribution to the Company, Dr. Khandaker stated, "I would like to continue to validate and grow the existing therapeutic portfolio at Nutra Pharma, including diseases of unmet medical needs. I simultaneously plan to work with the team in securing successful licensing contracts."
Dr. Khandaker serves on the Board of Directors of Nutra Pharma effective January 14, 2004.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Naming Dr. Tanvir Khandaker to the Nutra Pharma Board of Directors should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.